Skip to content
Review Open access

Exosome-mediated siRNA delivery in cancer: Loading strategies, targeting approaches, and therapeutic outcomes

Aug 2026 · DARU Journal of Pharmaceutical Sciences · Vol 34 · 0 citations · 225 references
Medicine

TL;DR

Challenges such as scalable production, cargo heterogeneity, and regulatory considerations remain, but ongoing advances in exosome engineering and patient-derived vesicles are poised to overcome these barriers.

Read PDF

Similar papers

Review Sep 2026

Engineering extracellular vesicles for targeted siRNA delivery: Advances, therapeutic applications, and clinical translation.

Small interfering RNA (siRNA) therapeutics have emerged as a transformative approach for sequence-specific gene silencing, offering the potential to treat a broad spectrum of diseases by selectively suppressing disease-associated genes. However, the clinical translation of siRNA remains limited by rapid enzymatic degra...

G. S. Amrish Varshan, S. Namasivayam · 0 citations
Review Open access Sep 2026

Research Progress on Tumor Microenvironment-Responsive siRNA Nanocarriers: Design Strategies, Delivery Efficiency, and Future Perspectives

This review comprehensively summarized the design principles and functional characteristics of TME-responsive siRNA delivery nanocarriers, with a focus on five major stimuli: pH, hypoxia, enzymes, glutathione (GSH), and reactive oxygen species (ROS).

Xiao-Xia Zhu, Gong-Hu Zhang, Lin Li et al. · 1 citation
Review Open access Aug 2026

THERAPEUTIC ROLE OF siRNA IN GASTRIC CANCER: GENE SILENCING MECHANISMS AND NANOCARRIER-BASED DELIVERY STRATEGIES.

Overall, siRNA-based strategies may play a crucial role in the future development of precision-oriented therapeutic frameworks in GC research, and this review emphasizes the integration of molecular target selection with delivery system design in a GC-specific context.

Gheysar Seifollahnezhad, B. Erdağ · 0 citations
Open access Aug 2026

An EGFR-Targeted Fusogenic Tandem Peptide for siRNA Delivery in Glioblastoma

These findings support GE11-599 as a promising siRNA delivery platform for targeting EGFR-expressing cancers and enhance cell-specific internalization and endosomal escape of siRNA in GBM cells, resulting in increased siRNA bioactivity and functional gene silencing.

Jessica R. Boulos, Karen Russi, Jordan Kinnitt et al. · 0 citations
Review Aug 2026

Engineered exosomes for CRISPR/Cas delivery to overcome oncogene-driven drug resistance.

The goal of this review is to outline a realistic pathway featuring proof-of-concept research, through discoveries to the creation of manufacturable, safe, and effective exosome/CRISPR therapeutics that can trigger durable therapeutic responses in resistant malignancies.

D. E. Uti · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.